Last reviewed: June 22, 2026
Last updated: June 22, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, the active ingredient in Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist that reduces appetite signaling in the brain and slows stomach emptying. Clinical trials show that semaglutide users achieve an average weight loss of 15 to 22 percent of their body weight within one year of treatment. Individual results vary significantly based on genetics, lifestyle adherence, and baseline metabolic health.
Average Weight Loss Results from Semaglutide Clinical Trials
The STEP trials, which evaluated semaglutide safety and efficacy, enrolled over 4,500 adults with obesity or overweight with weight-related conditions. Participants receiving the highest maintenance dose of 2.4 mg weekly lost an average of 15 pounds per month during the first several months, with cumulative losses reaching 50+ pounds by trial end. Placebo groups lost only 2 to 3 pounds on average, demonstrating that semaglutide's effect is substantially above background weight loss from diet and exercise alone.
Weight loss acceleration typically peaks between months four and ten of consistent therapy. After this peak phase, the rate of loss slows but continues as long as treatment persists. Discontinuation of semaglutide often results in partial weight regain, suggesting that ongoing therapy maintains the metabolic benefits achieved.
Why Individual Weight Loss Differs on Semaglutide
Not all patients respond identically to semaglutide therapy. Genetic variations in GLP-1 receptor sensitivity, appetite-regulating hormone pathways, and energy metabolism significantly influence how much weight a person loses. Some individuals lose over 25 percent of body weight, while others achieve 10 to 15 percent losses at the same dose, reflecting underlying biological differences in peptide signaling.
Adherence to dietary changes, baseline physical activity, sleep quality, stress levels, and insulin resistance all modify treatment outcomes. Patients who combine semaglutide with structured nutrition and consistent exercise achieve greater losses than those relying on medication alone. PlexusDx's Precision Peptide Genetic Test identifies personal genetic predispositions in GLP1R, GIPR, FTO, and MC4R pathways, allowing optimization of therapy for your unique biochemistry.
Monthly Weight Loss Expectations During Treatment
Initial weeks of semaglutide typically produce modest weight loss as the body adjusts to appetite suppression and gastric emptying changes. Most patients experience 1 to 3 pounds of loss per week during the first four to eight weeks, with acceleration as doses increase toward the 2.4 mg maintenance level. This early phase is driven by both reduced calorie intake and metabolic adaptation.
Plateau periods are normal and occur in most long-term users, usually around month six to nine of continuous therapy. These plateaus reflect the body's metabolic adaptation rather than treatment failure. Continuing semaglutide typically restarts weight loss momentum, and incorporating strength training or increasing physical intensity can help break through stalls.
Starting Semaglutide at PlexusDx: Dose, Cost, and Personalization
PlexusDx offers compounded semaglutide injections starting at $149 per month, with flat pricing regardless of dose level—your dose may need to go up, but your price won't. Treatment begins with a low dose of 0.25 mg weekly, increasing gradually to minimize gastrointestinal side effects while optimizing weight loss. All PlexusDx medications come from licensed 503A compounding pharmacies and are available across all 50 states without insurance requirements.
PlexusDx accepts HSA and FSA payments, reducing out-of-pocket costs for eligible patients. The optional Precision Peptide Genetic Test ($99 add-on after your first treatment month) reveals how your specific genetic variants influence GLP-1 and GIP receptor function, appetite control, and metabolic rate. This personalization helps predict your likely weight loss trajectory and guides dose optimization for maximum benefit.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the typical weight loss per month on semaglutide?
Most patients lose between 1 to 3 pounds per week during the first two months, with faster losses in weeks 2 through 8 as doses increase toward maintenance levels. Month-to-month averages typically range from 4 to 12 pounds during the active weight loss phase, though this slows after month six as the body adapts to the medication.
How much total weight can I lose on semaglutide?
Clinical trial data shows average losses of 15 to 22 percent of starting body weight over 68 weeks. This means a 250-pound person would lose approximately 37 to 55 pounds. However, individual results range from 10 to 30 percent depending on genetics, dietary adherence, exercise, and underlying metabolic health.
Is compounded semaglutide as effective as brand-name Wegovy?
PlexusDx's compounded semaglutide from licensed 503A pharmacies contains the same active pharmaceutical ingredient and follows equivalent manufacturing standards. Efficacy and weight loss outcomes are comparable to brand medications when doses are properly adjusted and monitored by healthcare providers.
Will I regain weight if I stop semaglutide?
Clinical data shows that stopping semaglutide often leads to partial weight regain over several months. Maintaining weight loss long-term typically requires continued therapy. Some patients achieve sustained results by maintaining the dietary and exercise habits developed during treatment, though individual outcomes vary significantly.
Can the Precision Peptide Genetic Test predict my weight loss results?
The PlexusDx Precision Peptide Genetic Test analyzes 150+ genetic insights across 14 pathways, including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 variants. These markers help predict your baseline appetite regulation, metabolic rate, and likely response to semaglutide, enabling personalized dosing strategies for optimal outcomes.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Often Should You Eat on Zepbound?
Where on Your Arm Can You Inject Ozempic?